Novo Nordisk new 2.9 billion kroner investment in Hillerød

Danish diabetes and obesity giant Novo Nordisk (NOV: N) has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark.

The new facility, covering 53,000 square meters, will be the company’s largest investment in advanced quality control to date. It underlines Novo Nordisk’s commitment to ensuring the highest quality standard across its product portfolio.

“This state-of-the-art quality control laboratory highlights Novo Nordisk's global growth journey and our dedication to innovation, says Erik Lorin Rasmussen, senior vice president of product supply, aseptic manufacturing. “As we expand our manufacturing capacity and anticipate new products to meet the growing global demand, this new quality control facility will play an important role in ensuring the quality of our products and position us to meet the evolving requirements of patients and regulators,” he added.